Professor Liu Yong is currently the deputy director and professor of the Biotherapy Center of Stanford University Medical College and the University of Arkansas Medical College. Medical practitioners in the United States and Hong Kong. Member of ASCO Immunotherapy Committee, editorial board member or full-time reviewer of several international basic and clinical journals related to tumor, immunity, virus and molecular biology. In China, he has been hired as a visiting professor or distinguished professor by Peking University Institute of Clinical Oncology, Cancer Center of Sun Yat-sen University, Nanfang Hospital, Fudan University, Chongqing Medical University and Hong Kong University of Science and Technology.

New progress has been made in targeted therapy of ACTL tumor cells developed by Professor Liu Yong. Two academic papers were published in the international journals of Biomedicine and Biotechnology and Tumor Immunology included in SCI, which mainly reported how to replace exogenous cytokines necessary in ACTL treatment with endogenous cytokines, which would help to improve the treatment effect, reduce the treatment cost, improve the quality of life of patients and benefit the majority of tumor patients. ACTL tumor cell targeted therapy technology was rated as the most important breakthrough in the field of tumor biotherapy in the first half of 20 10 by ASCO. For this reason, Professor Liu Yong obtained research funds from Roche Company in the United States to carry out related projects.